CDKN2A and cervical carcinoma: p16 immunohistochemistry is thus used as a marker for HPV positivity in several precancer and cancers, including cervical carcinoma, PeIN, and PeSCC (Bunker and Porter, 2016; Kravvas et al., 2022a; Sritippho et al, 2016).